ADMA Biologics Faces Class Action Lawsuit for Securities Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Lawsuit Background: ADMA Biologics is facing a class action lawsuit for securities fraud, primarily due to allegations that its reported 20% growth for 2025 was driven by a channel stuffing scheme, resulting in significant stock price drops and substantial investor losses.
- Stock Price Collapse: On March 24, 2026, ADMA's stock plummeted from $13.59 to $11.33, a 16.6% drop, followed by a further 15% decline the next day, reflecting severe market skepticism regarding its financial transparency.
- Legal Proceedings: The class action is pending in the U.S. District Court for New Jersey, with investors required to apply by August 10, 2026, to lead the case, indicating a loss of trust in the company's management.
- Market Reaction: A report by Culper Research exposed ADMA's alleged financial misconduct, leading to a downgrade by Cantor, which exacerbated investor panic and negatively impacted the company's market reputation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: ADMA Biologics is facing a class action lawsuit for securities fraud, primarily due to allegations that its reported 20% growth for 2025 was driven by a channel stuffing scheme, resulting in significant stock price drops and substantial investor losses.
- Stock Price Collapse: On March 24, 2026, ADMA's stock plummeted from $13.59 to $11.33, a 16.6% drop, followed by a further 15% decline the next day, reflecting severe market skepticism regarding its financial transparency.
- Legal Proceedings: The class action is pending in the U.S. District Court for New Jersey, with investors required to apply by August 10, 2026, to lead the case, indicating a loss of trust in the company's management.
- Market Reaction: A report by Culper Research exposed ADMA's alleged financial misconduct, leading to a downgrade by Cantor, which exacerbated investor panic and negatively impacted the company's market reputation.
See More
Class Action Lawsuit Filed Against ADMA Biologics
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, alleging that the company made materially false and misleading statements during this period, resulting in investor losses.
- Legal Procedure Requirements: Investors wishing to serve as lead plaintiffs must file a motion with the court by August 10, 2026, to establish their representative status in the class action, ensuring their active participation in the litigation process.
- Potential Compensation Mechanism: Investors joining the class action may be entitled to compensation without any upfront costs through a contingency fee arrangement, providing financial security and legal support for affected investors.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
ADMA Biologics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP has announced a class action lawsuit against ADMA Biologics on behalf of all investors who purchased its securities between August 9, 2024, and March 25, 2026, highlighting significant investor concerns regarding the company's transparency.
- Allegations of False Statements: The complaint alleges that ADMA Biologics made false and misleading statements during this period, failing to disclose related party transactions and inadequate internal controls, which severely undermined investor confidence in the company's operations.
- Stock Price Volatility: Following the March 24, 2026, report from Culper Research revealing that ADMA's revenue growth was achieved through channel stuffing, the stock price plummeted by $2.26, a 16.6% drop, further eroding market trust in the company.
- Legal Implications and Investor Rights: Investors may participate in the lawsuit to seek compensation, with Robbins LLP offering contingency-based representation, emphasizing the importance of corporate governance and investor rights protection.
See More
Class Action Filed Against ADMA Biologics for Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against ADMA Biologics, alleging violations of federal securities laws during the period from August 9, 2024, to March 25, 2026, affecting all investors who purchased ADMA securities during this timeframe.
- Allegations: The complaint claims that ADMA Biologics engaged in undisclosed related party transactions, utilized channel stuffing to inflate revenue, and lacked adequate internal controls, resulting in materially false and misleading statements regarding its business, operations, and prospects.
- Investor Action: Affected investors have until August 10, 2026, to request appointment as lead plaintiff in the case, allowing them to seek compensation without needing to serve as lead plaintiff to share in any recovery.
- Law Firm's Advantage: Bronstein, Gewirtz & Grossman operates on a contingency fee basis and has successfully recovered hundreds of millions for investors nationwide, focusing on restoring investor capital and ensuring corporate accountability to uphold market integrity.
See More
Investigation into ADMA Biologics Securities Litigation
- Lawsuit Investigation: Faruqi & Faruqi, LLP is investigating potential securities fraud claims against ADMA Biologics, urging investors who suffered losses between August 9, 2024, and March 25, 2026, to contact them before the August 10, 2026 deadline for legal recourse.
- False Statement Allegations: The lawsuit alleges that ADMA Biologics and its executives violated federal securities laws by failing to disclose related party transactions, engaging in channel stuffing to create a false appearance of revenue, and lacking adequate internal controls, resulting in materially misleading public statements about the company's operations and prospects.
- Stock Price Volatility: Following a report by Culper Research revealing ADMA Biologics' channel stuffing practices, the company's stock price plummeted by 29% over two trading days, from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, 2026, indicating significant market concerns regarding the company's financial health.
- Investor Rights Protection: Faruqi & Faruqi encourages all investors who purchased ADMA Biologics stock during the class period to contact the firm to understand their legal rights and potential participation in the class action, ensuring their ability to share in any recovery is not affected.
See More
ADMA Biologics Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: ADMA Biologics is facing a class action lawsuit for securities fraud, primarily alleging that its reported 20% growth for 2025 was achieved through a channel stuffing scheme, resulting in significant losses for investors.
- Stock Price Plunge: On March 24, 2026, ADMA's stock price plummeted by 16.6% from $13.59 to $11.33 per share following a report by Culper Research, indicating severe market concerns regarding its financial transparency.
- Subsequent Impact: In the following days, ADMA's stock continued to decline, dropping another 15% to $9.63 on March 25, and further to $8.29 by March 29, reflecting investor pessimism about the company's future prospects.
- Legal Consequences: Investors have until August 10, 2026, to apply to be lead plaintiffs in the case, and if successful, could impose legal liabilities on ADMA and its executives, affecting its future operations and market trust.
See More
ADMA Biologics Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: ADMA Biologics is facing a class action lawsuit for securities fraud, primarily due to allegations that its reported 20% growth for 2025 was driven by a channel stuffing scheme, resulting in significant stock price drops and substantial investor losses.
- Stock Price Collapse: On March 24, 2026, ADMA's stock plummeted from $13.59 to $11.33, a 16.6% drop, followed by a further 15% decline the next day, reflecting severe market skepticism regarding its financial transparency.
- Legal Proceedings: The class action is pending in the U.S. District Court for New Jersey, with investors required to apply by August 10, 2026, to lead the case, indicating a loss of trust in the company's management.
- Market Reaction: A report by Culper Research exposed ADMA's alleged financial misconduct, leading to a downgrade by Cantor, which exacerbated investor panic and negatively impacted the company's market reputation.
See More
Class Action Lawsuit Filed Against ADMA Biologics
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, alleging that the company made materially false and misleading statements during this period, resulting in investor losses.
- Legal Procedure Requirements: Investors wishing to serve as lead plaintiffs must file a motion with the court by August 10, 2026, to establish their representative status in the class action, ensuring their active participation in the litigation process.
- Potential Compensation Mechanism: Investors joining the class action may be entitled to compensation without any upfront costs through a contingency fee arrangement, providing financial security and legal support for affected investors.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
ADMA Biologics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP has announced a class action lawsuit against ADMA Biologics on behalf of all investors who purchased its securities between August 9, 2024, and March 25, 2026, highlighting significant investor concerns regarding the company's transparency.
- Allegations of False Statements: The complaint alleges that ADMA Biologics made false and misleading statements during this period, failing to disclose related party transactions and inadequate internal controls, which severely undermined investor confidence in the company's operations.
- Stock Price Volatility: Following the March 24, 2026, report from Culper Research revealing that ADMA's revenue growth was achieved through channel stuffing, the stock price plummeted by $2.26, a 16.6% drop, further eroding market trust in the company.
- Legal Implications and Investor Rights: Investors may participate in the lawsuit to seek compensation, with Robbins LLP offering contingency-based representation, emphasizing the importance of corporate governance and investor rights protection.
See More
Class Action Filed Against ADMA Biologics for Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against ADMA Biologics, alleging violations of federal securities laws during the period from August 9, 2024, to March 25, 2026, affecting all investors who purchased ADMA securities during this timeframe.
- Allegations: The complaint claims that ADMA Biologics engaged in undisclosed related party transactions, utilized channel stuffing to inflate revenue, and lacked adequate internal controls, resulting in materially false and misleading statements regarding its business, operations, and prospects.
- Investor Action: Affected investors have until August 10, 2026, to request appointment as lead plaintiff in the case, allowing them to seek compensation without needing to serve as lead plaintiff to share in any recovery.
- Law Firm's Advantage: Bronstein, Gewirtz & Grossman operates on a contingency fee basis and has successfully recovered hundreds of millions for investors nationwide, focusing on restoring investor capital and ensuring corporate accountability to uphold market integrity.
See More
Investigation into ADMA Biologics Securities Litigation
- Lawsuit Investigation: Faruqi & Faruqi, LLP is investigating potential securities fraud claims against ADMA Biologics, urging investors who suffered losses between August 9, 2024, and March 25, 2026, to contact them before the August 10, 2026 deadline for legal recourse.
- False Statement Allegations: The lawsuit alleges that ADMA Biologics and its executives violated federal securities laws by failing to disclose related party transactions, engaging in channel stuffing to create a false appearance of revenue, and lacking adequate internal controls, resulting in materially misleading public statements about the company's operations and prospects.
- Stock Price Volatility: Following a report by Culper Research revealing ADMA Biologics' channel stuffing practices, the company's stock price plummeted by 29% over two trading days, from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, 2026, indicating significant market concerns regarding the company's financial health.
- Investor Rights Protection: Faruqi & Faruqi encourages all investors who purchased ADMA Biologics stock during the class period to contact the firm to understand their legal rights and potential participation in the class action, ensuring their ability to share in any recovery is not affected.
See More
ADMA Biologics Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: ADMA Biologics is facing a class action lawsuit for securities fraud, primarily alleging that its reported 20% growth for 2025 was achieved through a channel stuffing scheme, resulting in significant losses for investors.
- Stock Price Plunge: On March 24, 2026, ADMA's stock price plummeted by 16.6% from $13.59 to $11.33 per share following a report by Culper Research, indicating severe market concerns regarding its financial transparency.
- Subsequent Impact: In the following days, ADMA's stock continued to decline, dropping another 15% to $9.63 on March 25, and further to $8.29 by March 29, reflecting investor pessimism about the company's future prospects.
- Legal Consequences: Investors have until August 10, 2026, to apply to be lead plaintiffs in the case, and if successful, could impose legal liabilities on ADMA and its executives, affecting its future operations and market trust.
See More
